OKUR News & Events

OnKure Therapeutics announced that it has entered into a securities purchase agreement for a private placement with certain institutional and accredited healthcare investors, raising gross proceeds of approximately $150M. OnKure intends to use the net proceeds from the private placement to fund the preclinical and clinical development of its next-generation PI3Ka pan-mutant-selective inhibitor candidates in breast cancer and vascular anomalies, as well as for working capital and general corporate purposes. Pursuant to the terms of the securities purchase agreement, OnKure has agreed to sell an aggregate of 26,713,636 shares of its Class A common stock at a purchase price of $4.15 per share and, in lieu of common stock, pre-funded warrants to purchase 9,430,959 shares of common stock at a purchase price of $4.1499 per pre-funded warrant. The pre-funded warrants have an exercise price of $0.0001 per share and will be immediately exercisable. The private placement is expected to close on March 31, subject to satisfactory closing conditions. With the net proceeds from the private placement, OnKure expects to extend its cash runway into 2029. Leerink Partners is acting as lead placement agent for the financing. Evercore ISI, LifeSci Capital, and Oppenheimer & Co. are serving as co-placement agents for the financing.

"We are pleased with the continued progress across our PI3Kalpha-focused pipeline, including the steady execution of the PIKture-01 trial of OKI-219. We look forward to sharing updated data from this trial later this month," said Nicholas Saccomano, president and CEO of OnKure. "We are also excited to announce our next-generation pan-mutant inhibitor development candidate for HR+ metastatic breast cancer this month and provide additional information on our program in vascular malformations later this year. Overall, we believe our progress to date underscores the power of our mutation-selective approach to PI3Kalpha inhibition and reinforces the momentum we are building as we work to deliver scientifically differentiated therapies to patients."

"We have made steady progress advancing our lead clinical development program, OKI-219, and are committed to leading the advancement of selective PI3Kalpha inhibitors for the treatment of patients with breast cancer and rare diseases. Based on its selectivity and safety profile, the differentiated value of OKI-219 is best demonstrated in early lines of therapy. This fact is at the heart of our clinical strategy. It is important to note that the single agent and fulvestrant dose ranging combination arms of our PIKture-01 trial have supported the expanded development of OKI-219 with the recent initiation of two triplet arms of the trial, including an evaluation of OKI-219 in combination with fulvestrant and ribociclib. We are at an exciting time in our company's history, and we look forward to sharing clinical data from several arms of our ongoing PIKture-01 trial of OKI-219 in the first quarter of 2026," said Nick Saccomano, President and Chief Executive Officer of OnKure.